Trevena Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Chesterbrook PA United States (2007)

Organization Overview

First Clinical Trial
2010
NCT01187836
First Marketed Drug
2020
oliceridine (Olinvyk)
First NDA Approval
2020
oliceridine (Olinvyk)
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

TREVENA | Trevena Inc.

Active Ingredients

Marketed Drugs (1)

oliceridine (Olinvyk) (2020 NDA)

Drugs in Phase 3 Trials (2)

morphine (5 trials)

oliceridine (Olinvyk) (10 trials)

Drugs in Phase 2 Trials (1)

trv120027 (3 trials)

Drugs in Phase 1 Trials (6)

glucose monohydrate (1 trial)

moxifloxacin (avelox) (1 trial)

oxycodone (oxycontin) (1 trial)

sodium chloride (1 trial)

trv250 (1 trial)

trv734 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Pain (Phase 3)

Fractures, Bone (Phase 2)

Heart Failure (Phase 2)

Kidney Diseases (Phase 1)

Renal Insufficiency (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial APIs: 9